+DayWeekMonth−
Friday · Nov 6, 2026 · Health Digest · regulation

FDA grants accelerated approval to Rybrevant Faspro for advanced head and neck cancer

In an open-label trial of 102 patients, the overall response rate was 42%, and 56% of responders had a response lasting six months or longer, the FDA said. The agency said currently approved therapies are associated with overall response rates of around 20% or less, and that this is the first approval in 10 years for patients with recurrent or metastatic HNSCC after platinum chemotherapy. The drug is not indicated for HPV-associated oropharyngeal squamous cell carcinoma.

Accelerated approval was based on overall response rate and duration of response, and confirmatory studies are required to verify clinical benefit, the FDA said. The approval was granted to Janssen Biotech, Inc., a Johnson & Johnson company, which also announced the decision.

Why it matters: The FDA said HNSCC is an aggressive disease with high unmet need, and the drug received Breakthrough Therapy designation for this indication.

References

  1. FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
    FDA · fda.gov · 2026-11-06
  2. Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
    Johnson & Johnson · jnj.com · 2026-11-06